Diagnostic Value of Gadoxetic Acid-Enhanced MRI for Differential Diagnosis of Rare Types of Hepatocellular Carcinoma
https://doi.org/10.37174/2587-7593-2024-7-3-54-61
Abstract
Purpose: The article describes a variety of liver lesions, hyperintensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI and the added value of gadoxetic acid in their differential diagnosis with consideration of its pharmacokinetics.
Material and methods: Gadoxetic acid-enhanced MRI scans of 19 patients with slight hyperintensity lesions in the hepatobiliary phase, were retrospectively assessed, the role of DWI in differential diagnosis of rare types of hepatocellular carcinoma (HCC) and focal nodular hyperplasia (FNH) was evaluated and the statistical analysis was performed.
Results: The combination of evaluated MRI semiotics features — hyperintensity in native, arterial, portal venous and hepatobiliary phases, slight hyperintensity on DWI (b-value 800 and b-value 400 s/mm2), rim enhancement (“capsule”) — enables differentiation of rare types of HCC and HCC with atypical enhancement in patients with FNH.
Conclusion: MRI with hepatobiliary contrast agents in junction with DWI increases the accuracy of identification of liver lesions and allows differentiation of rare types of HCC with atypical enhancement in patients with FNH without morphological verification.
About the Authors
B. M. Medvedeva
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Bela M. Medvedeva
AuthorID: 583878
4 Kashirskoe Shosse, Moscow 115478
Competing Interests:
The authors declare no conflict of interest
Yu. V. Molostova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Yuliya V. Molostova
4 Kashirskoe Shosse, Moscow 115478
Competing Interests:
The authors declare no conflict of interest
M. G. Lapteva
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Competing Interests:
Russian Federation
Mariya G. Lapteva
AuthorID: 1007893
4 Kashirskoe Shosse, Moscow 115478
Competing Interests:
The authors declare no conflict of interest
References
1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics. 2021. CA Cancer J Clin. 2021;71(1):7-33. https://doi.org/10.3322/caac.21669.
2. Fujita N, Nishie A, Asayama Y, et al. Hyperintense Liver Masses at Hepatobiliary Phase Gadoxetic Acid-enhanced MRI: Imaging Appearances and Clinical Importance. Radiographics. 2020;40(1):72-94. https://doi.org/10.1148/rg.2020190037.
3. Azusa K, Osamu M, Norihide Y, et al. Gadoxetic acid-en hanced MR imaging for hepatocellular carcinoma: molecular and genetic background. Eur Radiol. 2020;30(6):3438-47. https://doi.org/10.1007/s00330-020-06687-y.
4. Jian Z, Huichuan S, Zheng W, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edi tion). Liver Cancer. 2020;9(6):682-720.
5. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-50. https://doi.org/10.1002/hep.29913. PMID: 29624699.
6. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. https://doi.org/10.1016/j.jhep.2018.03.019.
7. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44(7):793-8. https://doi.org/10.1007/s00535-009-0056-4.
8. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. Radiology. 2010;256(3):817-26. https://doi.org/10.1148/radiol.10092214.
9. Goshima S, Kanematsu M, Kondo H, et al. Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique. AJR Am J Roentgenol. 2013;201(3):578-82. https://doi.org/10.2214/AJR.12.10034.
10. Reis MA, Baroni RH. Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease. Einstein (Sao Paulo). 2015;13(2):326-9. https://doi.org/10.1590/S1679-45082015RW3159.
11. Leonhardt M, Keiser M, Oswald S, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dis pos. 2010;38(7):1024-8. https://doi.org/10.1124/dmd.110.032862.
12. Purysko AS, Remer EM, Coppa CP, et al. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol. 2012;198(1):115-23. https://doi.org/10.2214/AJR.11.6836.
13. Kitao A, Matsui O, Yoneda N, et al. Gadoxeticacid-enhanced magnetic resonance imaging reflects co-activation of β-catenin and hepatocyte nuclear factor 4α in hepatocellular carcinoma. Hepatol Res. 2018;48(2):205-16. https://doi.org/10.1111/hepr.12911.
14. Kitao A, Matsui O, Yoneda N, et al. Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics. Radiology. 2015;275(3):708-17. https://doi.org/10.1148/radiol.14141315.
Review
For citations:
Medvedeva B.M., Molostova Yu.V., Lapteva M.G. Diagnostic Value of Gadoxetic Acid-Enhanced MRI for Differential Diagnosis of Rare Types of Hepatocellular Carcinoma. Journal of oncology: diagnostic radiology and radiotherapy. 2024;7(3):54-61. (In Russ.) https://doi.org/10.37174/2587-7593-2024-7-3-54-61
Views:
266
Email this article 